Microinvasive procedures have become established in glaucoma surgery and are preferred for patients with target pressure values that are not too low. Excimer laser trabeculotomy (ELT) represents such aminimally invasive approach and can easily be combined with cataract surgery. Over 12months the reduction in intraocular pressure (IOP), the number of antiglaucoma drugs and the incidence of adverse events were evaluated using the new EliosTM method (Elios Vision GmbH, Germering, Germany) for real-life data from aheterogeneous patient population undergoing ELT in combination with cataract surgery (phaco-ELT). In this study 20eyes of 13patients who underwent phaco-ELT were retrospectively analyzed. After standard phacoemulsification with posterior chamber lens implantation, 10microchannels were created using the excimer laser. The patients were followed for 12months and the intraocular pressure (IOP), number of antiglaucoma drugs and the occurrence of adverse events were analyzed. The average age was 65years. The preoperative IOP was 17.5(± 5.3) mm Hg. The mean IOP reduction was 4.8 mm Hg (27.4%, p < 0.001) on the first postoperative day, 3.2 mm Hg (18.3%, p = 0.22) after 6months and 2.5 mm Hg (14.3%, p = 0.14) at 12months. The number of antiglaucoma drugs decreased from an average of3.2 (± 1.3) preoperatively to0.5 (± 0.9) on day1 (p < 0.001), 1.9(± 1.2) after 6months (p = 0.008) and 2.2(± 1.3) after 12months (p = 0.013). In our cohort ELT in combination with cataract surgery is asafe minimally invasive procedure leading to an IOP reduction of 14.3% and areduction of pressure-lowering medication by1 active ingredient in patients with low initial pressure at 1‑year follow-up. As no implant is used in ELT and the conjunctiva remains untouched, subsequent procedures, including bleb-related surgery, are not negatively affected.